Osteopenia predicts outcomes in pancreatic cancer Study Background Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States and is projected to become the second by 2030. The unfavorable prognosis of PDAC can be attributed to late diagnosis, poor metabolic status, and the resistance of cancer
Tag: Pancreatic ductal adenocarcinoma
Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility
Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility Pancreatic ductal adenocarcinoma (PDAC) is the deadliest malignancy representing about 90% of all pancreatic cancers. PDAC progresses asymptomatically until death and is refractory to most treatment methods. Surgery is the most effective treatment. Nevertheless, it is well known that only 15-20% of PDAC
